FLGT News and Press, Fulgent Genetics Inc. From 11/04/19

Fulgent Genetics, Inc. (FLGT) Q3 2019 Results Earnings Conference Call November 04, 2019, 04:30 PM ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - CEO Paul Kim - CFO Conference Call Participants Erin Wright - Credit Suisse David Westenberg - Guggenheim Pr...

Fulgent Genetics (NASDAQ: FLGT ): Q3 Non-GAAP EPS of $0.14 beats by $0.11 ; GAAP EPS of $0.08 beats by $0.07 . More news on: Fulgent Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Third Quarter 2019 Results : Record billable tests of 20,697, growing 272% year over year Record revenue of $10.3 million, growing 84% year over year Gross Margin improves 8.9 percentage points year over year and 5.4 percentage points sequentially; cost per test improves 60% year ove...

TEMPLE CITY, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”) today announced that it will release its third quarter 2019 financial results after the market closes on Monday November 4, 2019. Th...

TEMPLE CITY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a provider of comprehensive genetic testing and Next Generation Sequencing (NGS) solutions, today announced the launch of Picture Geneti...

Fulgent Genetics stocks (NASDAQ:FLGT) rose 27% on Tuesday after the company posted a 56% rise in second-quarter revenues. For the three-month period ended June 30, Fulgent’s revenues rose to $8.4 million USD, up from $5.4 million USD for the same period last year. The Califo...

Fulgent Genetics, Inc. (FLGT) Q2 2019 Earnings Conference Call August 5, 2019 16:30 ET Company Participants Nicole Borsje - Head, IR Ming Hsieh - CEO Paul Kim - CFO Conference Call Participants Presentation Operator Good day, ladies and gentlemen, and welcome to the...

Fulgent Genetics (NASDAQ: FLGT ): Q2 Non-GAAP EPS of $0.06 beats by $0.06 ; GAAP EPS of $0.02 beats by $0.08 . More news on: Fulgent Genetics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Second Quarter 2019 Results : Record billable tests of 16,369, growing 187% year over year Record revenue of $8.4 million, growing 56% year over year Gross Margin improves more than 12 percentage points sequentially; cost per test improves by 44% sequentially Posts profit; GAAP inco...

TEMPLE CITY, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics”, “Fulgent” or the “company”) today announced the addition of Linda Marsh, Senior Executive Vice President of AHMC Healthcare, Inc. to it...